Evidence map›Paper›PMID 36249301›Full record

ArticleOphthalmology science2021

In Vitro Comparison of the

Travis K Redd, Maya Talbott, Vicky Cevallos, Prajna Lalitha, Gerami D Seitzman, Thomas M Lietman, Jeremy D Keenan

Open access · goldAbstract read
In one paragraph

Article in Ophthalmology science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Adjunctive povidone-iodine forAntimicrobial agents and chemotherapy · 2026
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Travis K ReddFrancis I. Proctor Foundation, University of California, San Francisco.
Maya TalbottFrancis I. Proctor Foundation, University of California, San Francisco.
Vicky CevallosFrancis I. Proctor Foundation, University of California, San Francisco.
Prajna LalithaAravind Eye Hospital, Madurai, India.
Gerami D SeitzmanFrancis I. Proctor Foundation, University of California, San Francisco.
Thomas M LietmanFrancis I. Proctor Foundation, University of California, San Francisco.
Jeremy D KeenanFrancis I. Proctor Foundation, University of California, San Francisco.
University of California, San Francisco · USAravind Eye Hospital · INOregon Health & Science University · US

Funding

Planning Grant for Parasitic Ulcer Treatment TrialR34EY022368 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KEENAN, JEREMY DAVID · 2012 to 2013
$438k
NEI NIH HHS R34 EY022368
6 · The paper itself

Abstract

Purpose: Design: Experimental study. Participants: In vitro Methods: The minimum cysticidal concentration (MCC) of povidone iodine, natamycin, and chlorhexidine was investigated using an established assay technique. The relative potency of each agent was estimated starting with concentrations commonly used in clinical practice and determining the number of two-fold dilutions required to reach the MCC. Statistical comparisons of relative potency were performed using bootstrap simulations and permutation tests. Main Outcome Measures: Minimum cysticidal concentration and the number of two-fold dilutions required to reach the MCC. Results: The MCC for chlorhexidine ranged from 3.1 to 25 μg/ml (median, 12.5 μg/ml; interquartile range [IQR], 6.25-12.5 μg/ml), the MCC for natamycin ranged from 390.6 to 3125 μg/ml (median, 390.6 μg/ml; IQR, 390.6-781.2 μg/ml), and the MCC for povidone iodine ranged from 0.3 to 78.1 μg/ml (median, 2.4 μg/ml; IQR, 0.6-9.8 μg/ml). Doses commonly used in clinical practice (povidone iodine 1%, natamycin 5%, and chlorhexidine 0.04%) were approximately 12, 7, and 5 two-fold dilutions higher than the drug's corresponding median MCC, respectively ( Conclusions: All 3 medications demonstrated in vitro cysticidal activity in each of the 9 isolates. The potency of 1% povidone iodine was greater than standard formulations of natamycin or chlorhexidine. Although its clinical efficacy is yet to be determined, povidone iodine may be considered as a potential adjuvant treatment in cases of recalcitrant

Indexed as

AcanthamoebaChlorhexidineIodineIQR, interquartile rangeMCC, minimum cysticidal concentrationNatamycin

Identifiers

PMID36249301
PMCPMC9560639
OpenAlexW3159867093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.